riluzole has been researched along with Neutropenia in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To enable patients with amyotrophic lateral sclerosis (ALS) who had not participated in previous riluzole trials to receive riluzole therapy, and 2." | 9.09 | The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. ( Debove, C; Powe, LK; Salzman, PM; Truffinet, P; Zeisser, P, 2001) |
| "Riluzole is the only disease-modifying drug approved for the treatment of amyotrophic lateral sclerosis (ALS), in which it has been demonstrated to extend survival." | 8.82 | The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. ( Bensimon, G; Doble, A, 2004) |
| " To enable patients with amyotrophic lateral sclerosis (ALS) who had not participated in previous riluzole trials to receive riluzole therapy, and 2." | 5.09 | The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. ( Debove, C; Powe, LK; Salzman, PM; Truffinet, P; Zeisser, P, 2001) |
| "Riluzole is the only disease-modifying drug approved for the treatment of amyotrophic lateral sclerosis (ALS), in which it has been demonstrated to extend survival." | 4.82 | The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. ( Bensimon, G; Doble, A, 2004) |
| "A 63-year-old woman with amyotrophic lateral sclerosis (ALS) presented with nausea, anorexia, and fever two weeks following inadvertent dose escalation of riluzole from 100 to 200 mg/d." | 3.70 | Reversible granulocytopenia in association with riluzole therapy. ( Khan, AM; North, WA; Sporn, JR; Yamase, HT, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weber, G | 1 |
| Bitterman, H | 1 |
| Bensimon, G | 1 |
| Doble, A | 1 |
| North, WA | 1 |
| Khan, AM | 1 |
| Yamase, HT | 1 |
| Sporn, JR | 1 |
| Debove, C | 1 |
| Zeisser, P | 1 |
| Salzman, PM | 1 |
| Powe, LK | 1 |
| Truffinet, P | 1 |
1 review available for riluzole and Neutropenia
| Article | Year |
|---|---|
The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Asthenia; Biotransformation; Chemical and Drug Induced Liver In | 2004 |
1 trial available for riluzole and Neutropenia
| Article | Year |
|---|---|
The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Amyotrophic Lateral Sclerosis; Exc | 2001 |
2 other studies available for riluzole and Neutropenia
| Article | Year |
|---|---|
Riluzole-induced neutropenia.
Topics: Aged; Amyotrophic Lateral Sclerosis; Female; Humans; Leukocyte Count; Neutropenia; Riluzole; Treatme | 2004 |
Reversible granulocytopenia in association with riluzole therapy.
Topics: Agranulocytosis; Amyotrophic Lateral Sclerosis; Female; Humans; Middle Aged; Neuroprotective Agents; | 2000 |